









Markets
/
Stocks
/
nasdaq-kmda
/

Kamada Ltd

KMDA

6.660USD

+0.040+0.60%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

382.98MMarket Cap

20.15P/E TTM



Kamada Ltd

6.660

+0.040+0.60%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Kamada Ltd

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Kamada Ltd's Score

Industry at a Glance

Industry Ranking

59 / 159

Overall Ranking

166 / 4614

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 3 analysts

Buy

Current Rating

16.000

Target Price

+140.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Kamada Ltd Highlights

StrengthsRisks

Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 24.44% year-on-year.

Fairly Valued

The company’s latest PE is 20.09, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 26.72M shares, decreasing 9.81% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 253.27K shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-07

The company's current financial score is 9.07, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 44.75M, representing a year-over-year increase of 5.37%, while its net profit experienced a year-over-year increase of 66.65%.

Score

Industry at a Glance

Previous score

9.07

Change



Financials

8.65

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.57

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

8.12

Key Metrics

Free cash flow

No Data

Kamada Ltd's Company Valuation

Currency: USD Updated: 2025-11-07

The company’s current valuation score is 7.35, which is higher than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is 20.09, which is 278.86% below the recent high of 76.10 and 636.46% above the recent low of -107.76.

Score

Industry at a Glance

Previous score

7.35

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 59/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-07

The company’s current earnings forecast score is 8.67, which is higher than the Pharmaceuticals industry's average of 7.77. The average price target for Kamada Ltd is 15.00, with a high of 20.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.67

Change

Support & Resistance

No Data

Analyst Rating

Based on 3 analysts

Buy

Current Rating

16.000

Target Price

+140.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Kamada Ltd

KMDA

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-07

The company’s current price momentum score is 6.66, which is lower than the Pharmaceuticals industry's average of 6.88. Sideways: Currently, the stock price is trading between the resistance level at 7.04 and the support level at 6.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.40

Change

0.26

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.039

Sell

RSI(14)

44.253

Neutral

STOCH(KDJ)(9,3,3)

20.728

Neutral

ATR(14)

0.201

High Vlolatility

CCI(14)

-177.587

Sell

Williams %R

80.357

Oversold

TRIX(12,20)

-0.023

Sell

StochRSI(14)

18.308

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

6.750

Sell

MA10

6.839

Sell

MA20

6.836

Sell

MA50

6.887

Sell

MA100

7.175

Sell

MA200

7.026

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-07

The company’s current institutional recognition score is 3.00, which is lower than the Pharmaceuticals industry's average of 5.76. The latest institutional shareholding proportion is 46.33%, representing a quarter-over-quarter decrease of 16.91%. The largest institutional shareholder is James Simons, holding a total of 832.00K shares, representing 1.44% of shares outstanding, with 0.32% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

First Israel Mezzanine Investors Ltd.

22.08M

Gov Financial Holdings, Ltd.

2.80M

-1.96%

Renaissance Technologies LLC

Star Investors

832.00K

+2.93%

Recanati (Leon Yehuda)

631.14K

Wells Fargo Advisors

610.47K

+0.31%

Tsur (David)

607.93K

Dimensional Fund Advisors, L.P.

411.59K

+0.80%

Essex Investment Management Company, LLC

323.83K

More Investment House Ltd.

329.70K

-0.20%

Acadian Asset Management LLC

263.56K

+3.10%

Risk Assessment

Currency: USD Updated: 2025-11-07

The company’s current risk assessment score is 4.24, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.94. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.